Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo

Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo

Although sorafenib, an oral multikinase inhibitor, was approved as a treatment drug of advance hepatocellular carcinoma (HCC), treatment efficacy still requires improvement. Searching for the adjuvant reagent for enhancing sorafenib efficacy remains as a critical issue. Sorafenib has been proved to...

Full description

Bibliographic Details
Main Authors: Jiann-Hwa Chen, I-Tsang Chiang, Fei-Ting Hsu
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:Cancers
Subjects:
magnolol
sorafenib
akt
hepatocellular carcinoma
Online Access:https://www.mdpi.com/2072-6694/12/1/87

Similar Items

Similar Items